40637HAD1
Halozyme Therapeutics, Inc.
Could not find a ticker for this position, may be a filing error
A San Diego biopharma company whose ENHANZE technology uses a naturally occurring enzyme to temporarily loosen the gel-like tissue under the skin, letting large-volume biologic medicines be injected in minutes instead of slowly dripped over hours. Its partners sell drugs built on this platform, such as DARZALEX FASPRO and HYQVIA, and it also makes auto-injector devices and its own products like XYOSTED. Co-founded in 1998 by Dr. Gregory Frost, the company's name blends "hyaluronidase" and "enzyme" — the very molecule its science revolves around.
CONVERTIBLEUnderlying: HALOCUSIP: 40637HAD1HealthcareUS1 derivative reporter
Convertible bond maturing March 1, 2027
No tracked superinvestor held this security as stock in this period — only the derivative positions below reference it.
Derivative Reporters
Investor
Kind
13F reported value
Quantity
Change
